Disease · MONDO_0006594
pemphigus
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. pemphigus. Diseases, record MONDO_0006594. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006594
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs19
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RITUXIMAB | CHEMBL1201576 | Antibody | Approval | EMA Human Drugs | 10 | 8 | 8 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 2 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| BETAMETHASONE | CHEMBL632 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| BETAMETHASONE SODIUM PHOSPHATE | CHEMBL1200762 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| HYDROCORTISONE | CHEMBL389621 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| MYCOPHENOLIC ACID | CHEMBL866 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 19
See all 19 drugsTargets7
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 8 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 2 | B-lymphocyte antigen CD20 binding agent | Approval | https://conductscience.org/library/genes/931 | Drugs and targets |
| BTK | Tyrosine-protein kinase BTK | 1 | Tyrosine-protein kinase BTK inhibitor | Phase 3 | https://conductscience.org/library/genes/695 | Drugs and targets |
| FCGRT | IgG receptor FcRn large subunit p51 | 1 | IgG receptor FcRn large subunit p51 inhibitor | Unknown | https://conductscience.org/library/genes/2217 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Early phase 1 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 3 | https://conductscience.org/library/genes/3614 | Drugs and targets |
| IMPDH2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 3 | https://conductscience.org/library/genes/3615 | Drugs and targets |
Trials17
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05000216 | COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders | Phase 2 | 258 | 2025-08-22 | Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS) | ELASOMERAN, TOZINAMERAN | Its record names the disease | ClinicalTrials.gov |
| NCT00656656 | Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus | Phase 2 | 23 | 2016-12-22 | Pemphigus | DEXAMETHASONE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00483119 | Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus | Phase 2 | 9 | 2016-02-18 | Pemphigus Vulgaris | CYCLOPHOSPHAMIDE, HUMAN IMMUNOGLOBULIN G | Its record names the disease | ClinicalTrials.gov |
| NCT01313923 | Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus | Early phase 1 | 3 | 2016-03-25 | Pemphigus | SIROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT06663943 | A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313. | Phase 1/2 | 100 | Pemphigus Disease, Pemphigus Vulgaris (PV) | LUMROTATUG | Its record names the disease | ClinicalTrials.gov | |
| NCT00784589 | Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus | Phase 3 | 90 | Pemphigus Disease | PREDNISONE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT03790293 | Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial | Phase 3 | 80 | Autoimmune Diseases | PREDNISOLONE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT02993133 | Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. | Phase 3 | 53 | Autoimmune Bullous Dermatose | MYCOPHENOLIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT06654817 | Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris | 38 | Pemphigus, Pemphigus Vulgaris (PV) | OFATUMUMAB | Its record names the disease | ClinicalTrials.gov | ||
| NCT00010413 | Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus | Phase 2 | 35 | Pemphigus | CYCLOPHOSPHAMIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 17
See all 17 trialsComparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Group A vs Group B: serious adverse events | 1 of 5 | 1 of 4 | 9 | NCT00483119 | Trial comparisons |
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection | 0 of 1 | 0 of 1 | 2 | NCT05000216 | Trial comparisons |
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any Grade 1 or Higher Adverse Events Related to Study Vaccine | 0 of 1 | 0 of 1 | 2 | NCT05000216 | Trial comparisons |
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any New Onset Chronic Medical Conditions (NOCMCs) | 0 of 1 | 0 of 1 | 2 | NCT05000216 | Trial comparisons |
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any Medically Attended Adverse Events (MAAEs) | 0 of 1 | 0 of 1 | 2 | NCT05000216 | Trial comparisons |
Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) vs Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX): Percent of Stage 2 Pediatric Participants Who Experience Any Serious Adverse Events (SAEs) | 0 of 1 | 0 of 1 | 2 | NCT05000216 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006594
GET https://conductscience.org/api/diseases/v1/MONDO_0006594/drugs